Mortimer Ian

PRESIDENT & CEO, DirectorXenon Pharmaceuticals Inc. (XENE) · full profile →Form 4 · filed Mar 11, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$17.0M
Net Open-Market Flow
-$17.0M
Transactions
21
15 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 10, 2026Sell(S)11K$60.11$677K15K
Mar 9, 2026Sell(S)22K$58.81$1.3M59K
Mar 9, 2026Sell(S)32K$59.88$1.9M28K
Mar 9, 2026Sell(S)22K$60.49$1.3M6K
Mar 9, 2026Option exercise(M)25K$3.10$78K31K
Mar 9, 2026Sell(S)12K$59.50$743K19K
Mar 9, 2026Sell(S)10K$60.47$609K8K
Mar 9, 2026Sell(S)2K$61.26$150K6K
Mar 9, 2026Option exercise(M)105K$4.75$499K111K
Mar 9, 2026Sell(S)43K$59.26$2.6M73K
Mar 9, 2026Sell(S)62K$60.08$3.7M6K
Mar 9, 2026Option exercise(M)65K$9.44$614K71K
Mar 9, 2026Sell(S)65K$62.06$4.0M6K
Mar 9, 2026Option exercise(M)20K26K
Mar 9, 2026Option exercise(M)75K$8.40$630K81K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(M)65K$00
Mar 9, 2026Option exercise(M)75K$00
Mar 9, 2026Option exercise(M)105K$00
Mar 9, 2026Option exercise(M)20K$00
Mar 9, 2026Grant(A)20K$020K
Mar 9, 2026Option exercise(M)25K$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-102666) within minutes of acceptance. Every field above traces to the original document. Verify it directly: